about
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysisPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesEarly invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraManagement of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelinesRoutine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraAcute management of unstable angina and non-ST segment elevation myocardial infarctionBivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-AnalysisEfficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysisThe REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndromePerspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization : Fifty Years of Revascularization: Where Are We and Where Are We Heading?Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionAnticoagulation in the management of non-ST-segment elevation acute coronary syndrome.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Acute coronary syndromes: diagnosis and management, part IHeparin-induced thrombocytopenia: treatment options and special considerations.Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudinThe direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT.The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin.Bivalirudin: a review of the pharmacology and clinical application.New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.Safety of bivalirudin in patients with coronary artery disease.Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial.Predicting and evaluating the effect of bivalirudin in cardiac surgical patients.A Predictive Model for the Anticoagulant Bivalirudin Administered to Cardiac Surgical Patients.Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review.Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.Successful use of bivalirudin in place of heparin infusion for pulmonary vein isolation using a cryoballoon catheter in a patient with heparin allergy.Recent advances in antithrombotic therapy after acute coronary syndrome.Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary interventionSafety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary eventsFondaparinux and acute coronary syndromes: update on the OASIS 5-6 studies.Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.Temporal trends in percutaneous coronary intervention--associated acute cerebrovascular accident (from the 1998 to 2008 Nationwide Inpatient Sample Database).Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics.
P2860
Q22242057-F6D0A271-0B79-468E-8B19-2D78E9342931Q24202522-03AFACFB-6BC4-4322-AAF3-FA8588F7D085Q24202999-827059B7-AFAD-4C75-AFEB-809AFE89C046Q24235385-904CCA21-81F2-4F62-92B6-EC161C25AC94Q24236794-4D84427A-D3DD-423E-9A95-C54F7A177BEBQ24653318-B7F27C7E-0DFD-46AF-9510-73BCD42959EEQ26471900-DC1E6205-442D-45A6-A4CC-29770A99F9D8Q26783157-9A3935A3-B382-4775-A3E2-E74045CC687BQ26798653-A12A736E-F22C-40BF-AC89-A3303AACBE5EQ26853150-AF6D4F04-3173-4027-8827-B0D25F4D4C43Q27000201-92DBC185-EDFF-495A-B933-3788C3FE0BFCQ28087099-606AFB8F-2B7D-41F7-8DDC-E311C4CDCB14Q28191096-036E1576-F14D-4E05-B120-75A33C5DEE2FQ30402038-0C74FE45-C3B4-4F8D-B916-B3E3837398A6Q30438893-51881B8E-3D32-4592-83AA-4FC1AC85CC86Q30490718-1AA98A39-D472-405A-B667-215881695262Q33374658-3FC4FE09-9C26-498F-BC9E-5B1E94544315Q33381356-C3FCA018-1390-40B9-8D52-A6F50EA0C97BQ33385970-A7A0B465-EC60-47A9-9815-3DDD5378D41DQ33387192-0D09D5A8-8079-48C4-936F-AB16526A5CD2Q33391341-6A6D981A-AC91-4DC2-8C74-048F278345E9Q33392973-81F75620-396E-453E-9D57-30A002BC0635Q33397359-999759C4-DCA8-43B8-B55A-4FA4F193CB33Q33397635-76887DF8-63B8-4471-BCEE-8E98DEA67E19Q33399307-4989F8D8-FD9D-4FDD-A8A3-90D4302DF447Q33400450-65C4E937-A097-4AA2-8CF1-5265C5FBA8BDQ33410211-2A333D70-0F3C-47A6-9C4A-411DB94A19B2Q33414958-8241B706-BFA9-45E2-B2D1-232725E32FBDQ33433514-CD4A228A-FB97-4388-BFEB-1C0B39890D66Q33434702-304921F3-7A72-4909-BA67-1EA45E503487Q33435616-8E1D2FB8-A7A6-4990-9325-64B229ED370DQ33441751-5F34020A-9397-4E0D-89D7-E9EF40C49BB1Q33590548-2B17DF51-C0A4-4D2E-9946-DB979306BACAQ33701953-E8D7F4CB-9F5A-4E62-97A4-C7A30A63FA7FQ33715389-277E000F-FF1F-45BA-ACB4-1A8AC8A827A1Q33728256-6C398954-C10B-40C6-AC66-22DE7D451A9EQ33797609-4CF686C9-9680-4E99-B56B-C7549C2FFC75Q33824750-A8C0C30C-EE38-4DAD-997A-DDBBB38C3940Q33874044-4097D7B6-CD2C-48A9-B7AF-DEC392EED701Q33876187-CFB203F8-B777-4B28-ADFD-CFC7A7F34502
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Bivalirudin for patients with acute coronary syndromes
@ast
Bivalirudin for patients with acute coronary syndromes
@en
Bivalirudin for patients with acute coronary syndromes
@nl
type
label
Bivalirudin for patients with acute coronary syndromes
@ast
Bivalirudin for patients with acute coronary syndromes
@en
Bivalirudin for patients with acute coronary syndromes
@nl
prefLabel
Bivalirudin for patients with acute coronary syndromes
@ast
Bivalirudin for patients with acute coronary syndromes
@en
Bivalirudin for patients with acute coronary syndromes
@nl
P2093
P50
P3181
P356
P1476
Bivalirudin for patients with acute coronary syndromes
@en
P2093
Angel R Cequier
Antonio Colombo
Brent T McLaurin
David A Cox
Frederick Feit
Gregg W Stone
Hans-Jürgen Rupprecht
Harald Darius
Harvey D White
James H Ware
P304
P3181
P356
10.1056/NEJMOA062437
P407
P577
2006-11-23T00:00:00Z